01 Industry overview
The bio technology industry at a glance
Biotechnology is a rapidly expanding, healthcare-led industry: the global market was valued at $1.38 trillion in 2025, while U.S. bioscience employment reached 2.31 million workers.
- $1.38T[107]
- Global market size, 2025
- 14.3%[107]
- Global CAGR, 2026–2034
- 2.31M[22]
- U.S. bioscience jobs, 2025
- 41%[108]
- EU pharma spending on biologics, 2024
- Market size
- Fortune Business Insights estimated the global biotechnology market at $1.376 trillion in 2025 and $1.492 trillion in 2026. The European Commission separately reported that EU biological-medicine sales reached €95 billion in 2024.[107][108]
- Forecast & CAGR
- The global biotechnology market is projected to reach $4.335 trillion by 2034, implying a 14.3% compound annual growth rate from 2026 to 2034. Grand View Research’s narrower market definition estimated a 13.96% CAGR from 2024 to 2030, illustrating the effect of scope differences between market studies.[107][109]
- Market share & regions
- North America accounted for 43.34% of the global biotechnology market in 2025, according to Fortune Business Insights. The European Commission reported that the United States held 63% of global health-biotechnology venture capital, compared with 14% for China and 7% for the European Union.[107][108]
- Segmentation
- Biotechnology is segmented by technology and application. In 2025, bioprocessing technologies were the largest technology segment in Fortune Business Insights’ market model, while pharmaceutical and biotechnology companies were projected to represent 53.8% of the market in 2026; major application areas include biopharmaceutical discovery, cell and gene therapy, molecular diagnostics, RNA medicines and precision medicine.[107]
- Key players & concentration
- The sector combines a large base of small and emerging companies with highly influential pharmaceutical and biotechnology groups, including Eli Lilly, AbbVie, Roche and Pfizer. In the United States, the bioscience industry comprised more than 156,000 business establishments and 2.31 million workers in 2025, indicating a broad company base rather than a market dominated by only a few establishments.[22][107]
- Trends, drivers & challenges
- Growth is being driven by genomics, gene editing, synthetic biology, bioprocessing, artificial intelligence and expanding applications in healthcare, agriculture and industrial production. Financing remains uneven: EY reported $68.5 billion raised by biopharma companies in 2025, while emerging companies continued to face financing pressure and patent-cliff risks.[107][23]
- Consumer behavior & competition
- Demand is increasingly concentrated in biological medicines and advanced therapies: biological products represented 41% of total pharmaceutical spending in the EU in 2024. Competition is also increasingly international, with the United States leading health-biotechnology venture capital at 63% globally, ahead of China at 14% and the EU at 7%.[108]
- M&A
- Biotechnology, pharmaceutical and medical-technology companies each accounted for about 30% of 2025 deal volume in McKinsey’s healthcare M&A analysis. Overall average deal size increased nearly 63% in 2025 from the prior year, indicating a shift toward fewer, larger transactions.[58]
- Regulation
- The U.S. Food and Drug Administration maintains separate approval pathways and annual records for biological products and biologics license applications. In the EU, multinational clinical-trial applications averaged 113 days for approval, compared with about 60 days in the United States and China, according to the European Commission.[60][108]
- Latest news
- EY’s 2026 Biotech Beyond Borders report found that biotech revenues reached $232 billion in 2025, with 72 companies generating more than $500 million in sales. The report also said biotech market capitalization rose 28.8% to $1.65 trillion, while total industry capital raised increased 26%.[23]
02 Ranking
Top 10 Companies in the Bio Technology Industry
The leading companies in the bio technology industry, ranked on market impact, performance, momentum, innovation and brand popularity.
Updated November 10, 2026 · Next review December 10, 2026
Eli Lilly stands out for biopharmaceutical medicines because it reported $65.2 billion in 2025 revenue and invested $13.3 billion in R&D, while Roche focuses on biopharmaceuticals and molecular diagnostics since pharmaceuticals sales reached CHF 47.7 billion in 2025.
Ranked by Overall score · How we score ↓
Editor's top 3 picks
Where to start, by need.
#1 Overall · Leader in biopharmaceutical medicines
Eli Lilly
US
Ranked #1 · 9.8 · Biopharmaceutical medicines
Why we picked it: It reports $13.3 billion in R&D on $65.2 billion in 2025 revenue, alongside a 40.4% operating margin.
Leader in biopharmaceuticals & diagnostics
Roche
CH
Ranked #2 · 9.2 · Biopharmaceuticals & diagnostics
Why we picked it: It combines medicines and diagnostics, reporting CHF 47.7 billion in 2025 pharmaceuticals sales.
Leader in diabetes & obesity biologics
Novo Nordisk
DK
Ranked #3 · 9.1 · Diabetes & obesity biologics
Why we picked it: It reports 45.6 million people living with diabetes and obesity in 2025 and a 41.3% operating margin.
Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.
Full ranking
| # | Company | Overall ↓ | Impact | Performance | Momentum | Innovation | Company snapshot |
|---|---|---|---|---|---|---|---|
| 1 | Eli Lilly Biopharmaceutical medicines · US | 9.8 | 9.7 | 9.9 | 9.9 | 9.9 | |
Company snapshot · Eli Lilly · Data as of November 10, 2026 Lilly reported $65.2 billion in 2025 revenue and invested $13.3 billion in R&D.[110]
| |||||||
| 2 | Roche Biopharmaceuticals & diagnostics · CH | 9.2 | 9.9 | 8.0 | 8.7 | 9.9 | |
Company snapshot · Roche · Data as of November 10, 2026 Roche combines medicines and diagnostics, with pharmaceuticals sales of CHF 47.7 billion in 2025.[111]
| |||||||
| 3 | Novo Nordisk Diabetes & obesity biologics · DK | 9.1 | 9.7 | 8.7 | 8.0 | 9.9 | |
Company snapshot · Novo Nordisk · Data as of November 10, 2026 Novo Nordisk reached 45.6 million people living with diabetes and obesity in 2025.[112]
| |||||||
| 4 | Vertex Pharmaceuticals Cystic fibrosis & gene editing · US | 9.0 | 8.9 | 8.9 | 8.8 | 9.9 | |
Company snapshot · Vertex Pharmaceuticals · Data as of November 10, 2026 Vertex reported $12.0 billion in 2025 revenue, led by cystic-fibrosis therapies and new launches.[113]
| |||||||
| 5 | AbbVie Biopharmaceutical medicines · US | 9.0 | 9.7 | 8.6 | 8.4 | 9.0 | |
Company snapshot · AbbVie · Data as of November 10, 2026 AbbVie reported $61.2 billion in 2025 revenue and approximately 57,000 employees.[114]
| |||||||
| 6 | Amgen Innovative biologic medicines · US | 8.9 | 9.2 | 8.7 | 8.5 | 9.0 | |
Company snapshot · Amgen · Data as of November 10, 2026 Amgen describes itself as a biotechnology company and served approximately 17 million patients in 2025.[115]
| |||||||
| 7 | Incyte Targeted oncology and immunology medicines · US | 8.7 | 8.1 | 9.6 | 9.0 | 8.2 | |
Company snapshot · Incyte · Data as of November 10, 2026 Incyte reported $5.14 billion in 2025 revenue from products, royalties and collaborations.[116]
| |||||||
| 8 | Regeneron Pharmaceuticals Antibody medicines and genetic technologies · US | 8.6 | 9.0 | 8.1 | 7.3 | 9.9 | |
Company snapshot · Regeneron Pharmaceuticals · Data as of November 10, 2026 Regeneron generated $14.3 billion in 2025 revenue and developed 16 approved treatments in-house.[117]
| |||||||
| 9 | BioMarin Pharmaceutical Genetic disorders and enzyme therapies · US | 8.3 | 7.8 | 8.2 | 8.6 | 9.0 | |
Company snapshot · BioMarin Pharmaceutical · Data as of November 10, 2026 BioMarin develops targeted therapies for genetic disorders using enzyme and molecular biology expertise.[118]
| |||||||
| 10 | Ionis Pharmaceuticals Antisense medicines and RNA technology · US | 8.1 | 7.0 | 8.4 | 9.2 | 8.5 | |
Company snapshot · Ionis Pharmaceuticals · Data as of November 10, 2026 Ionis generated $944 million in 2025 revenue from commercial products and partnered R&D programs.[119]
| |||||||
How we score
- Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
- Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
- Momentum (20%): growth trajectory and future potential.
- Innovation (15%): R&D intensity and how technologically advanced the company is.
Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.
Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.
Cadence Recalculated when new figures are published; next review December 10, 2026.
Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.
Cite this ranking
APA
Samuel Norberg. (2026, November 10). Top 10 companies in the bio technology industry. In Bio Technology Industry Statistics. Gitnux. https://gitnux.org/bio-technology-industry-statistics/#top-companies
Employment share by Member State in the EU blue biotechnology sector
Others holds the largest share at 35%.
03 Trends & forecasts
Top 10 Bio Technology Industry Trends & Forecasts 2027
What is changing in the bio technology industry, with the evidence behind each trend and a forecast for 2027.
Forecasts were generated by an AI model from the cited evidence. They are estimates, not guarantees.
01Biologics keep gaining treatment share
High confidenceBiologic medicines represented 44% of EU pharmaceutical value at list prices in 2025, up from 28% in 2014. In the United States, biologic-medicine spending reached $262 billion in 2024, more than half of total medicine spending.[64]
Forecast 2027: Biologics should remain the main source of biotechnology demand in 2027, supported by oncology, immunology, metabolic disease and rare-disease treatments. Their share of pharmaceutical spending is likely to rise again, although biosimilar competition will moderate net growth.
02Biosimilar competition expands rapidly
High confidenceIQVIA estimates that U.S. biosimilar spending could reach $20 billion to $49 billion in 2027, with at least 10 molecules facing competition during the period covered by its forecast. Separately, 118 U.S. biologics are expected to lose patent protection between 2025 and 2034, representing approximately $234 billion in sales exposure.[64]
Forecast 2027: In 2027, biosimilars should capture more volume in mature immunology, oncology and supportive-care markets. Price reductions and payer incentives will expand access, but uptake will remain uneven where provider reimbursement or interchangeability rules are unfavorable.
03Cell and gene therapies broaden
High confidenceThe FDA reported that its biologics center had approved close to 50 cell and gene therapies over the decade through January 2026. Its current approved-product list includes therapies for cancer, inherited disorders, hemophilia, sickle-cell disease and tissue repair.[60]
Forecast 2027: Approvals and commercial launches should continue to increase in 2027, especially for ex vivo cell therapies and targeted gene replacement or editing. Adoption will remain constrained by manufacturing capacity, specialized administration and high upfront treatment costs.
04Gene-editing regulation becomes more flexible
Medium confidenceIn January 2026, the FDA announced a more flexible approach to chemistry, manufacturing and controls requirements for cell and gene therapies. In July 2026, it expanded Casgevy's approval to children aged two years and older with sickle-cell disease or transfusion-dependent beta thalassemia.[60]
Forecast 2027: By 2027, sponsors should use more adaptive manufacturing and development strategies for gene-editing products, particularly for serious diseases with limited alternatives. Regulatory flexibility will shorten some development timelines, but long-term safety and durability evidence will remain essential.
05AI investment concentrates in drug R&D
High confidenceEY reported that more than 88% of biobucks AI investment was concentrated in research and development, particularly target identification, drug design and clinical-trial patient recruitment. EY also reported that biotech financing reached $68.5 billion in 2025, up 11% from 2024.[23]
Forecast 2027: In 2027, AI should move from pilot projects toward embedded use in target selection, molecule design, biomarker discovery and trial operations. Spending will favor platforms that demonstrate higher clinical success or shorter development cycles rather than general-purpose tools.
06Genomics moves toward cheaper, richer data
High confidenceThe NIH identified rapid, low-cost sequencing and genotyping, functional genomics, genome editing, epigenome editing and transcriptome editing as priority technology-development areas in 2026. The agency emphasized improvements in genomic resolution, throughput and cost.[120]
Forecast 2027: In 2027, biotechnology companies should combine whole-genome, transcriptomic and clinical data more routinely in discovery and precision-medicine programs. Falling data-generation costs will expand use, while data quality, privacy and interpretation remain key bottlenecks.
07Late-stage financing outpaces early-stage funding
High confidenceEY reported that U.S. biotech venture capital totaled $20.6 billion in 2025, with $10 billion invested across 254 late-stage rounds, while early-stage deal value and volume declined. Fundraising by biotech companies outside the commercial leaders reached $58.9 billion, the highest level since 2021, but capital remained unevenly distributed.[23]
Forecast 2027: The 2027 funding market should continue to reward clinical proof, differentiated platforms and near-term commercial opportunities. Seed and preclinical companies are likely to rely more heavily on licensing, partnerships, milestone financing and smaller syndicates.
08Biotech deals become fewer and larger
High confidenceEY reported that deals valued at $5 billion or more accounted for 59% of biotech deal spending in 2025, compared with a five-year average of 51%. The average deal size reached its highest level in five years, while oncology and neurology led large transactions by value.[23]
Forecast 2027: In 2027, strategic buyers should continue prioritizing targeted acquisitions of validated assets over broad platform purchases. Deal volume may remain selective, but competition for late-stage oncology, neurology, metabolic and immune assets should keep headline valuations elevated.
09Domestic biomanufacturing capacity expands
High confidenceEY reported that industry leaders pledged more than $370 billion toward domestic manufacturing in response to geopolitical and tariff pressures. The FDA's 2026 PreCheck pilot selected seven participants to expand U.S. pharmaceutical manufacturing and supply-chain resilience, including facilities for cell and gene therapies.[23][60]
Forecast 2027: In 2027, companies should increase regional and dual-source manufacturing for biologics, viral vectors and cell therapies. New capacity will improve resilience, but higher domestic capital and operating costs will keep manufacturing economics under pressure.
10EU policy shifts toward biotech competitiveness
Medium confidenceThe proposed European Biotech Act is designed to streamline clinical-trial, cell-and-gene-therapy and broader biotechnology rules. The Commission's architecture includes the BiotechEU initiative, which is intended to mobilize €10 billion over 2026 and 2027.[108]
Forecast 2027: During 2027, EU institutions and member states should focus on implementing or preparing the Act's funding, clinical-trial and manufacturing measures. The policy direction should improve support for European biotech, although practical effects will vary by national permitting and health-system adoption.
04 Statistics
Technology & Innovation
Adoption data shows AI and automation moving from pilots into production and core functions, with 48% integrating AI into core business functions in 2026.
AI in the bio technology industry
- 5% of life-sciences laboratories reported using AI agents in production in 2026.[1]
- 35% of surveyed life-sciences leaders reported spending fewer than 10 hours with risk counterparts on generative-AI initiatives in 2024.[2]
- 15% of life-sciences organizations reported having at least 11 generative-AI use cases in production in 2024.[3]
- 46% of large biopharma companies reported being able to attract and hire skilled AI talent in 2024, versus 17% of small companies.[4]
- Only 17% of small biopharma companies reported being able to attract and hire skilled AI talent in 2024.[4]
- 48% of surveyed life-sciences organizations were strategically integrating AI into core business functions in 2026.[5]
Automation in the bio technology industry
- 63% of biopharma survey respondents used robotics and automation in 2023.[6]
- 55% of surveyed biopharmaceutical organizations already used inventory-management software in 2025.[7]
- 38% of small biopharmaceutical companies relied on manual laboratory processes in 2025.[7]
- 58% of surveyed biopharmaceutical organizations planned to automate repetitive tasks in 2025.[7]
- 65% of surveyed biopharmaceutical organizations planned to adopt new inventory-management software in 2025.[7]
- 81% of surveyed laboratory-technology manufacturers identified cost pressure as a driver of automation and robotics investment in 2026.[8]
Digital Transformation in the pharmaceuticals and biotech sector (sector benchmark)
- 45% of pharmaceutical companies surveyed were pursuing digitalization as an innovation or technology in 2024.[9]
- 13% of clinical-research organizations surveyed reported a comprehensive AI-driven digital programme in 2024.[10]
- 35% of clinical-research organizations surveyed were piloting digital technologies in 2024, up from 29% in 2019.[10]
- 58.1% of global pharmaceutical-industry survey respondents were in the pilots or systematic-ongoing-actions stages of Pharma 4.0 adoption in 2023.[11]
- 15.1% of global pharmaceutical-industry survey respondents reported that Pharma 4.0 digital transformation had not started in 2023.[11]
Technology Adoption in the pharmaceuticals and biotech sector (sector benchmark)
- 55% of biopharma AI adopters reported using AI in process development in 2024.[4]
- 63% of global biopharma respondents had adopted robotics and automation in 2023.[6]
- 37% of small biopharma respondents reported that more than 60% of their R&D laboratory instruments had automated data capture in 2024.[12]
- 70% of global biopharma respondents had adopted an R&D data platform in 2023.[6]
- 59% of global biopharma respondents had adopted artificial intelligence or machine learning in 2023.[6]
Cloud Computing in the pharmaceuticals and biotech sector (sector benchmark)
- 18% of global biopharma respondents had adopted cloud-based scientific software or SaaS in 2023.[6]
- 77% of life-sciences commercial IT leaders reported investing primarily in cloud infrastructure in 2024.[13]
- 17% of large biopharma respondents had adopted cloud-based scientific software or SaaS in 2024.[4]
- 49% of biopharma survey respondents reported using cloud computing to facilitate day-to-day work in 2021.[14]
- 23% of small biopharma respondents had adopted cloud-based scientific software or SaaS in 2024.[4]
Big Data in the pharmaceuticals and biotech sector (sector benchmark)
05 Statistics
Data & Analytics
Data readiness is the main constraint for scaling AI, with 96% of commercial biopharma leaders saying data was not well-structured or AI-ready for scaling in 2025.
Business intelligence in the bio technology industry
- 33% of life-sciences organizations use AI capabilities in regulatory affairs and government relations, according to KPMG’s 2026 survey.[5]
- 36% of life-sciences organizations use AI capabilities in discovery sciences and early research, according to KPMG’s 2026 survey.[5]
- 57% of biotech and biopharma organizations use API integrations or programmatic access to query external R&D data, according to a 2025 survey.[12]
- 46% of life-sciences organizations use AI capabilities in pricing and market access, according to KPMG’s 2026 survey of technology executives.[5]
- 37% of life-sciences organizations use AI capabilities in M&A and licensing, according to KPMG’s 2026 survey.[5]
- 57% of life-sciences organizations use AI capabilities in data science and biostatistics, the highest current-use rate among business areas in KPMG’s 2026 survey.[5]
Data analytics in the bio technology industry
- 50% of biotech and biopharma organizations use AI for data analytics and visualization, while 32% are piloting it, according to a 2025 survey.[12]
- 89% of life-sciences and biotechnology respondents said a strong data foundation was the most critical factor for AI deployment, according to Salesforce’s 2025 survey.[16]
- 29% of biotech and biopharma organizations use AI for ADME analysis, according to a 2025 survey.[12]
- 76% of biotech and biopharma organizations use AI for literature review and knowledge extraction, according to a 2025 survey of AI-using R&D organizations.[12]
- 71% of biotech and biopharma organizations use AI for protein-structure or protein-property prediction and analysis, according to a 2025 survey.[12]
- 66% of biotech and biopharma organizations use AI for scientific reporting and internal communication, according to a 2025 survey.[12]
Data Quality in the pharmaceuticals and biotech sector (sector benchmark)
- Across 125 senior U.S. life-sciences leaders, 81% said accuracy and confidence in data were critical components of AI success in biopharma in 2026.[17]
- Across 116 commercial biopharma leaders in the United States, Europe and Asia-Pacific, 96% said their data was not well-structured or AI-ready for scaling in 2025.[17]
- Across 116 commercial biopharma leaders in the United States, Europe and Asia-Pacific, 81% identified data quality as their top data issue for the next 12 months in 2025.[17]
- Across 116 commercial biopharma leaders in the United States, Europe and Asia-Pacific, 73% reported significant data quality issues in 2025.[17]
- Across 500 pharmaceutical and biotechnology executives globally, 44% said their organization was prepared on data quality and completeness in 2025.[18]
Data Governance in the pharmaceuticals and biotech sector (sector benchmark)
- Across 200 global life-sciences R&D respondents, 49% called for more data-governance frameworks to make data FAIR at scale in 2024.[19]
- Across 11 pharmaceutical regulatory organizations, 9% reported a comprehensive approach to onboarding standards such as IDMP and XEVMPD, with regular source qualification, connected systems and data cleaning in 2023.[20]
- Across 200 global life-sciences R&D respondents, 51% identified maintenance and management of data standards and ontologies as a key FAIR-data need in 2024.[19]
- Across 200 global life-sciences R&D respondents, 46% called for templates for standardization and metadata to make data FAIR at scale in 2024.[19]
- Across 500 pharmaceutical and biotechnology executives globally, 54% said their organization was prepared on data governance in 2025.[18]
KPIs in the bio technology industry
- 74% of biotechnology, pharmaceutical and life-sciences executives expected AI opportunities to affect revenue targets, according to ZS’s 2025 survey.[21]
- 73% of biotechnology, pharmaceutical and life-sciences executives expected AI opportunities to affect productivity targets, according to ZS’s 2025 survey.[21]
- 77% of biotechnology, pharmaceutical and life-sciences executives said their companies had adjusted or planned to overhaul enterprise data strategies, according to ZS’s 2025 survey.[21]
- 60% of biotechnology, pharmaceutical and life-sciences executives planned to improve how technology organizations demonstrate business-outcome measures in 2025, according to ZS’s survey.[21]
- 32% of biotechnology, pharmaceutical and life-sciences executives identified unpredictable AI outputs as a challenge to scaling AI solutions, according to ZS’s 2025 survey.[21]
- 52% of biotechnology, pharmaceutical and life-sciences companies planned to improve organizational agility in 2025, according to ZS’s survey.[21]
06 Statistics
Strategy & Growth
Scale and capital signals remain elevated, with U.S. bioscience economic output at $3.19 trillion in 2025 and biotechnology market capitalization rising to $1.65 trillion.
Growth in the bio technology industry
- 9.67 million U.S. jobs were supported by the bioscience industry’s direct, indirect and induced effects in 2025.[22]
- 22% was the increase in U.S. bioscience establishments from 2021 to 2025.[22]
- $3.19 trillion was the total economic output generated by the U.S. bioscience industry in 2025.[22]
- $68.5 billion was raised by biopharma companies in 2025, an 11% increase from 2024.[23]
- 2.31 million people were employed by U.S. bioscience companies in 2025.[22]
- $1.65 trillion was the biotechnology industry’s market capitalization in 2025, up 28.8% year over year.[23]
Differentiation in the bio technology industry
- 14% of 2024 biopharma partnerships involved metabolic-disease programs.[24]
- 10% of 2024 biopharma partnerships involved cardiovascular programs.[24]
- $132,000 was the average annual pay for a U.S. bioscience worker in 2023, reflecting the sector’s concentration in skilled and specialized roles.[22]
- 85% of 2024 biopharma partnerships concerned preclinical or Phase I assets.[24]
- 28.8% was the increase in biotechnology market capitalization in 2025, reaching $1.65 trillion.[23]
- 34% of biotechnology follow-on financings rebounded in 2025, led by large rounds for orphan-disease and immunology companies.[23]
Mergers and acquisitions in the bio technology industry
- 288 global life-sciences M&A deals were recorded in 2023, with total disclosed value of $209.730 billion.[25]
- $135 billion was the estimated value of biotechnology and biopharma acquisitions in 2025.[22]
- 266 global life-sciences M&A deals were recorded in 2022, with total disclosed value of $243.960 billion.[25]
- 452 M&A deals were recorded across healthcare and life sciences in 2024.[26]
- 274 M&A deals were recorded across healthcare and life sciences in 2023.[26]
- 297 M&A deals were recorded across healthcare and life sciences in 2022.[26]
Strategic partnerships in the bio technology industry
- $45 million was the median upfront payment for biopharma licensing agreements in 2024.[24]
- $11.3 billion was the aggregate upfront value of biopharma partnerships announced in 2024.[24]
- 13% of biopharma partnerships in 2024 involved Phase I assets.[24]
- 100 biopharma collaboration partnerships were announced in 2024.[24]
- $610 million was the median total deal value for biopharma licensing agreements in 2024.[24]
- $46 million was the median upfront payment for biopharma collaborations in 2024.[24]
07 Statistics
People & Workforce
Workforce pressure coexists with hybrid and remote options, with 22% of surveyed U.S. biopharma organizations anticipating layoffs in 2026.
Hiring in the bio technology industry
- 68,581 unique U.S. life sciences job postings were published per month on average during 2021–2022.[27]
- 33% of U.S. life sciences companies reported that recent hires represented less than 20% of their total workforce in 2025.[28]
- 29% of U.S. biopharma organizations expected to hire in technology in 2026.[29]
- 38% of U.S. biopharma organizations expected to hire in manufacturing and production in 2026.[29]
- 41% of U.S. biopharma organizations surveyed expected their number of open roles to increase in 2026.[29]
Employee retention in the bio technology industry
- 26.5% of general and administrative employees at surveyed Massachusetts biotechnology companies worked on-site in 2025–2026.[30]
- 47% of surveyed U.S. biopharma organizations said employee turnover remained unchanged from the previous year in 2026.[29]
- 22% of surveyed U.S. biopharma organizations anticipated layoffs in 2026, creating a stated retention and job-security pressure.[29]
- 35% of global life sciences employees surveyed in 2026 were considering leaving their current organization.[31]
- Lower employee turnover and greater retention rates were reported across the U.S. life sciences industry during the two years covered by the 2025 workforce survey.[28]
Remote Work in the pharmaceuticals and biotech sector (sector benchmark)
- Across U.S. life sciences companies, 65.9% reported implementing, expanding, or considering remote-work options for at least some employees in 2023.[32]
- Among life-sciences companies with remote-work options, 50.0% cited competition with technology and other industries as a reason for their policy in 2023.[32]
- Among privately held life-sciences companies surveyed, 21.7% had some portion of their workforce fully remote in 2025.[33]
- Across U.S. chemical and pharmaceutical manufacturers, 5.7% of positions were fully remote in the 2024 hiring outlook survey.[34]
Hybrid Work in the pharmaceuticals and biotech sector (sector benchmark)
- Among surveyed life-sciences companies in the MassBio Human Resources Roundtable, 97% planned to implement hybrid work models for the long term in 2022.[35]
- Across U.S. chemical and pharmaceutical manufacturers, 44.5% of positions were fully hybrid in the 2024 hiring outlook survey.[34]
- Among surveyed life-sciences employers in the BioHealth Capital Region, 60% expected at least a hybrid workforce after the pandemic in 2021.[36]
- Among life-sciences CEOs, 83% expected corporate employees whose roles were traditionally office-based to work in a hybrid environment three years after the 2024 survey.[5]
Upskilling in the bio technology industry
- 22.9% of surveyed U.S. life sciences companies rated apprenticeships very important for entry-level technical hires in 2025.[28]
- 21.5% of surveyed U.S. life sciences companies reported high-school mentorships in 2025.[28]
- 77.6% of surveyed U.S. life sciences companies offered internships through four-year colleges or universities in 2025.[28]
- 56.2% of surveyed U.S. life sciences companies reported classroom engagement with community colleges in 2025.[28]
- More than 2,000 students across over 30 U.S. states had been assessed by the Bioscience Core Skills Institute by 2025.[28]
Employee Engagement in the pharmaceuticals and biotech sector (sector benchmark)
- Across the Culture Amp pharmaceuticals benchmark, 17% of employees disagreed that they had seen positive changes based on recent employee survey results in July 2026.[37]
- At Amneal Pharmaceuticals, global employee engagement reached 88% in the company’s 2024 reporting year.[38]
- Across the Culture Amp pharmaceuticals benchmark, 91% of employees agreed they understood how their work contributed to company goals in July 2026.[37]
- Across the Culture Amp pharmaceuticals benchmark, 18% of employees were thinking of or actively seeking another job in July 2026.[37]
DEI in the bio technology industry
08 Statistics
Customer & Sales
Commercial measurement relies on retention and service KPIs, with 95% Standard BioTools customer retention in 2024 for its specified customer group.
Customer experience in the bio technology industry
- 94% of surveyed oncology KOLs said scientific exchange between clinical experts and pharmaceutical companies was becoming more important in 2024.[17]
- 28 life-science brands were evaluated across product awareness, selection, service and support touchpoints in the 2024 BioInformatics study.[40]
- 68% of surveyed medical-information companies tracked customer-satisfaction surveys as a key performance indicator in 2024.[41]
- 50.5% of global life-science quality professionals tracked customer satisfaction through complaints, feedback or returns in 2024.[42]
- 86% of surveyed oncology KOLs in the United States and Europe were satisfied or very satisfied with pharma engagement in 2024.[17]
Customer retention in the bio technology industry
- 106% was Revvity Signals’ net retention rate on renewals in 2024.[43]
- 95% was Standard BioTools’ year-over-year customer retention rate in 2024 for its specified customer group.[44]
- 90% of Teknova’s annual revenue came from customers purchasing more than $10,000 annually in 2023.[44]
- 15% of Teknova’s customer base consisted of customers purchasing more than $10,000 annually in 2023.[44]
- 92% or higher was Standard BioTools’ customer retention rate in each of the ten fiscal years before 2024.[44]
Customer acquisition in the bio technology industry
- 159.89% was Indegene’s customer revenue-retention rate in fiscal 2022.[45]
- 129.90% was Indegene’s customer revenue-retention rate in fiscal 2021.[45]
- 122.83% was Indegene’s customer revenue-retention rate in fiscal 2023, including expansion from existing customers rather than new customer acquisition.[45]
- 69% or more of Indegene’s operating revenue came from its 20 largest biopharmaceutical customers in fiscal 2021, 2022 and 2023.[45]
- 5 new customer meetings were booked in one month by a niche biotech product company using targeted outbound outreach.[46]
Customer loyalty in the bio technology industry
- 44% of oncology KOLs perceived a lack of coordination or alignment across biopharma functions in 2024, a reported barrier to consistent customer relationships.[17]
- 32% of surveyed medical-information companies measured customers’ likelihood to recommend information to a colleague in 2024.[41]
- 86% of oncology KOLs were satisfied or very satisfied with pharma engagement, indicating positive relationship sentiment, in the United States and Europe in 2024.[17]
- −10% was the average Net Promoter Score for pharmaceutical companies among more than 700 U.S. healthcare providers surveyed in 2025.[21]
- 32% of oncology KOLs said their satisfaction varied substantially across companies, indicating limited consistency in biopharma loyalty-building experiences in 2024.[17]
Lead generation in the bio technology industry
- 3.8% was the reply rate from a one-month targeted outbound campaign for a niche biotech product company.[46]
- 11 interested leads were generated from 810 contacts reached in a one-month biotech outbound campaign.[46]
- 21% of science sales and marketing professionals identified events as a top lead source in the 2026 survey.[47]
- 31% of surveyed life-sciences professionals defined organizational growth primarily as generating more leads in the 2026 State of Life Sciences Marketing Report.[48]
- 60% of surveyed life-sciences professionals reported using LinkedIn as a marketing channel in the 2026 State of Life Sciences Marketing Report.[48]
09 Statistics
Marketing & Brand
Marketing spend shifts toward interactive development and AI content creation, with 78% of life science marketers using AI to generate written content in 2024.
Marketing in the bio technology industry
- 20% of life science marketers classified website, app and interactive development as a major budget item in 2023.[49]
- 75% of life science companies using external marketing agencies were mostly or completely satisfied with their agencies’ work in 2023.[49]
- 55% of life science marketers classified trade shows and events as a major budget item in 2023.[49]
- Nearly 50% of life science companies increased spending on interactive development in 2023.[49]
- 85% of 2024 life science marketing-survey participants were directly involved in marketing decisions.[50]
Digital marketing in the bio technology industry
- 18% of science marketers increased or greatly increased display-ad budgets in 2024.[51]
- 49% of science marketers were likely to increase online spending in 2025.[51]
- 16% of science marketers were likely to increase offline spending in 2025.[51]
- 21% of science marketers increased or greatly increased social-ad budgets in 2024.[51]
- 78% of science marketers used AI to generate written content in 2024.[51]
Branding in the bio technology industry
- 67% of science companies used events in their email marketing in 2024.[51]
- 61% of science companies used webinars in their email marketing in 2024.[51]
- 18.2% of science companies sent newsletters weekly in 2024.[51]
- 68% of science companies used newsletters in their email marketing in 2024.[51]
- 31% of science companies had no newsletter in 2024.[51]
Influencer Marketing in the pharmaceuticals and biotech sector (sector benchmark)
- 50% of healthcare and pharmaceutical marketers reported dedicated and growing budgets for creator or influencer marketing in 2026, globally.[52]
- 50% of physicians in Europe, APAC and North America said healthcare influencer or KOL content had changed their prescribing choices in 2024.[53]
- 10% of healthcare and pharmaceutical marketers said they did not invest in creator or influencer marketing in 2026, globally.[52]
- 44% of physicians in Europe, APAC and North America said healthcare influencer or KOL content had changed their perception of a medication in 2024.[53]
- 4.5% of high-engagement prescription-drug promotion posts across Facebook, Instagram, TikTok and YouTube came from pharmaceutical companies in the United States in 2025.[54]
10 Statistics
Operations & Execution
Manufacturing execution centers on standardization and process issues, and the network and productivity constraints show up as specific operational targets in 2025.
Process optimization in the bio technology industry
- 67% of biopharma respondents identified data analytics, cloud computing, simulation and modeling as relevant Industry 4.0 technologies in 2019.[55]
- 42% of biopharma manufacturing respondents rated product characterization as somewhat challenging in 2019.[55]
- 54% of biopharma respondents cited lack of standardization as the leading single-use technology challenge in 2019.[55]
- 59% of biopharma manufacturing respondents identified process robustness as a major challenge in 2019.[55]
- 52% of surveyed biopharmaceutical manufacturers used process analytical technology in manufacturing operations.[56]
Operational efficiency in the bio technology industry
- 6% to 7% is the potential year-over-year productivity improvement from an integrated digital lean-production system in biopharma.[57]
- 15 to 20 internal commercial manufacturing sites is the average network size for large biopharmaceutical companies.[57]
- 33 of 50 global life-sciences leaders ranked accelerating decision-making among their top three simplification priorities.[58]
- 5% was the decline in biopharmaceutical manufacturing productivity after 2018, according to McKinsey analysis.[58]
- 14.6% of biopharmaceutical manufacturing respondents selected productivity and efficiency as their single most needed improvement in 2025.[59]
Quality management in the bio technology industry
- 60% of global pharmaceutical manufacturing inspections received voluntary-action-indicated status in FY2025.[60]
- 17.9% of Indian pharmaceutical manufacturing inspections received official-action-indicated status in FY2025.[60]
- 37% of surveyed pharmaceutical quality professionals named root-cause analysis the leading reason deviations get delayed or stuck in 2026.[61]
- 81% of surveyed pharmaceutical quality professionals identified root-cause analysis as the deviation-management stage involving the most manual work in 2026.[61]
- 8.0% of Chinese pharmaceutical manufacturing inspections received official-action-indicated status in FY2025.[60]
Supply chain in the bio technology industry
- 12 to 15 months is the reported wait time for GMP-grade viral vectors in biotechnology supply chains.[62]
- 43.9% of biopharmaceutical respondents reported difficulty finding microbial-fermentation CDMO capacity in 2026.[63]
- 40% of global cell-therapy trials were conducted in China, according to a 2025 biotechnology supply-chain assessment.[62]
- 80% of global contract development and manufacturing capacity is located in Asia and Europe, according to a 2025 biotechnology supply-chain assessment.[62]
- More than 50% of India’s key starting materials depend on Chinese supply, according to a 2025 biotechnology supply-chain assessment.[62]
Outsourcing / Offshoring in the pharmaceuticals and biotech sector (sector benchmark)
- 54% of global biotech and pharma companies outsourced regulatory activities in 2024, according to an IQVIA industry report.[64]
- 40% of surveyed pharma and biotech CDMO decision-makers identified small-molecule API as the most outsourced product in July 2024.[65]
- 74% of surveyed pharmaceutical and biotech R&D leaders ranked patient recruitment among the top five drug-development activities likely to be outsourced in 2023.[9]
- 12% of total API volume used in the United States was produced domestically in 2024, with most supply coming from India and the European Union.[66]
- 41% of surveyed pharmaceutical and biotech R&D leaders increased their use of functional-service-provider outsourcing versus two years earlier in 2023.[9]
11 Statistics
Finance & Pricing
Margins and valuation dispersion remain central, with a median gross margin of 56.0% for listed biotechnology companies at September 30, 2026.
Pricing strategy in the bio technology industry
- 33% was the annual increase in inflation-adjusted launch prices after adjustment for drug characteristics including gene and cell therapies, orphan products and therapeutic area.[67]
- 51% was the inflation-adjusted increase in median annual net launch price for drugs launched between 2022 and 2024, from just over $180,000 to more than $270,000.[67]
- 9.1% per year was the average increase in U.S. list prices for 602 branded drugs from 2007 to 2018.[54]
- 45.2% was the decrease in trimmed-mean drug prices in Germany ten years after launch.[54]
- 33.4% was the decrease in trimmed-mean drug prices in Germany five years after launch.[54]
Cost reduction in the bio technology industry
- $500 per gram to under $100 per gram was the reduction in monoclonal-antibody manufacturing cost reported over the past decade.[68]
- 42% more production runs were possible at large scale after moving to single-use technologies.[68]
- 42% was the reported cost saving at 200-liter scale after adopting single-use bioprocessing technology.[68]
- 23% was the reported cost saving at 2,000-liter scale after adopting single-use bioprocessing technology.[68]
- 187 biotech-company layoff announcements were recorded in 2023, 57% more than in 2022.[69]
Profitability in the bio technology industry
- 6.5 times revenue was the median enterprise-value-to-sales multiple for listed biotechnology companies at September 30, 2026.[70]
- 68% of listed biotechnology companies had negative EBITDA at September 30, 2026.[70]
- 10.3% was the average return on capital generated by biopharmaceutical companies between 2022 and 2024.[71]
- 56.0% was the median gross margin for listed biotechnology companies at September 30, 2026.[70]
- 71.0% was Bio-Techne’s adjusted gross margin in fiscal 2024.[44]
Financial planning in the bio technology industry
- $2.6 billion was raised by China-based biopharma companies in venture capital during 2024.[22]
- $4.31 million was the average amount raised per biotechnology company in the BioAlberta 2025 survey.[72]
- $19 billion was invested in U.S. biopharma venture capital in 2024.[22]
- $68.5 billion was raised by the biotechnology industry in 2025, an 11% increase from 2024.[23]
- 28% of Texas public biotechs had cash sufficient for less than two years but more than one year in 2023.[23]
12 Statistics
Product & Service
Pipeline and regulatory throughput connect to commercialization timing, including 7 cell and gene therapies approved in the United States in 2024.
Product development in the bio technology industry
- 191 pipeline projects were reported by AstraZeneca in 2024, including 169 in clinical development worldwide.[73]
- 5,800 biotechnology companies were estimated globally in 2025, up from fewer than 1,200 in 2001.[74]
- 3.9% was the decline in the biopharma drug-development pipeline at the start of 2026, to 22,940 drugs.[75]
- 107 priority-gap projects were in discovery or preclinical development in the 2024 Access to Medicine Index.[76]
- 253 of 808 pipeline projects targeted an established priority research gap in the 2024 Access to Medicine Index.[76]
Product lifecycle in the bio technology industry
- 16% of drugs launched within 10 years of patent filing during 2015–2024 were neurology products.[77]
- Approximately 40% of FDA approvals in 2024 used the 505(b)(2) pathway, according to a biotechnology analysis.[78]
- 7 cell and gene therapies were approved in the United States in 2024.[24]
- 14.4 years was the median time from first patent to U.S. launch in 2024.[77]
- 59 new molecules were approved by the U.S. Food and Drug Administration in 2024.[24]
After-sales in the bio technology industry
- 25% of preventive-maintenance visits failed to prevent a follow-up service event at bottom-performing companies in 2025.[79]
- 3 times more service visits occurred at bottom-performing medical-device companies because of longer times between failures in 2025.[79]
- 68% of public-health laboratories with high-resolution mass spectrometry relied on instrument-vendor service agreements in 2021.[80]
- 68% of surveyed laboratories said management of instrument uptime and service was adequate in a 2010 survey.[81]
- 82% of laboratory-equipment service issues were resolved on the first visit by top-performing companies in 2025.[79]
Value proposition in the bio technology industry
- $223 billion in federal taxes was generated or supported by the U.S. bioscience industry in 2025.[22]
- $3.19 trillion was the total U.S. economic output associated with the bioscience industry in 2025.[22]
- 84% higher was the average U.S. bioscience-worker wage than the overall private-sector average in 2025.[22]
- $145,188 was the average annual wage for U.S. bioscience workers in 2025.[22]
- $1.69 trillion was the bioscience industry’s contribution to U.S. value added in 2025.[22]
13 Statistics
Sustainability & Ethics
Energy and emissions management is quantified across large biopharmaceuticals, with an average reduction of about 5.3% per year in Scope 1 and 2 since 2015.
Sustainability in the bio technology industry
- Around 5.3% per year was the average reduction in Scope 1 and 2 emissions among the 25 largest biopharmaceutical companies since 2015.[82]
- 24% of evaluated European biotechnologies and pharmaceutical companies had conducted an energy audit during the previous three years.[83]
- 35% of evaluated European biotechnologies and pharmaceutical companies had quantitative greenhouse-gas-reduction targets.[84]
- 50–60% higher energy costs were reported for biopharmaceutical manufacturing processes than for other industrial sectors.[83]
- 77% of evaluated European biotechnologies and pharmaceutical companies had implemented actions to reduce greenhouse-gas emissions and energy consumption.[83]
ESG in the bio technology industry
- 49 was the average ESG score for water management among evaluated European biotechnologies and pharmaceutical companies.[83]
- 60 was the average ESG score for business ethics among evaluated European biotechnologies and pharmaceutical companies.[83]
- 60% of the reviewed biotech companies disclosed ESG information in 2022.[85]
- 36% of 74 small and mid-sized biotech companies provided ESG information in voluntary standalone corporate responsibility reports in 2023.[86]
- 15 was the average ESG score for biodiversity among evaluated European biotechnologies and pharmaceutical companies.[83]
Ethics in the bio technology industry
- 64% of surveyed biotech companies disclosed or planned to disclose human rights as an ESG topic.[85]
- 26% of surveyed biotech companies disclosed or planned to disclose ethical research as an ESG topic.[85]
- 39% of surveyed bioethicists considered human challenge trials ethically impermissible under the stated conditions.[87]
- 61% of surveyed bioethicists considered human challenge trials ethically permissible when other research standards were met.[87]
- 31% of United States researchers and 28% of European researchers cited excessive cost as a concern about future human gene therapy.[88]
CSR in the bio technology industry
- 56% of surveyed biotech companies disclosed or planned to disclose drug access as an ESG topic.[85]
- 40% of surveyed biotech companies disclosed or planned to disclose community engagement as an ESG topic.[85]
- 0.58% of sales represented social-contribution activities by global pharmaceutical companies in Korea in 2019.[89]
- 30.2 billion Korean won was spent on social-contribution activities by global pharmaceutical companies in Korea in 2019.[89]
- 18% of 50 U.S. biotech companies disclosed ESG information in proxy statements in 2021.[85]
Circular economy in the bio technology industry
- 84.3% of biomanufacturing respondents used single-use bioreactors in 2020.[90]
- 84.3% of biomanufacturing respondents used buffer containers in 2020.[90]
- 88.8% of biomanufacturing respondents used empty bags in 2020.[90]
- 89.9% of biomanufacturing respondents used depth filters in 2020.[90]
- 37.0% of bioprocessing respondents were satisfied with current recycling programs for single-use systems in 2024.[7]
Carbon footprint in the bio technology industry
- 638 publicly listed and 290 privately held biotech and pharmaceutical companies were covered by the carbon-footprint study.[91]
- 24% of European biotechnologies and pharmaceutical companies had conducted an energy audit during the previous three years.[83]
- 5.3% per year was the reduction in Scope 1 and 2 emissions among the 25 largest biopharmaceutical companies since 2015.[82]
- 77% of European biotechnologies and pharmaceutical companies had implemented actions to reduce greenhouse-gas emissions and energy consumption.[83]
- 9% of European biotechnologies and pharmaceutical companies had climate targets validated by the Science Based Targets initiative.[84]
14 Statistics
Risk, Compliance & Legal
Compliance and cyber risk appear as operational constraints, with 98% of surveyed pharmaceutical firms experiencing at least one cybersecurity intrusion in the 12 months covered by Fortinet’s 2021 survey.
Compliance in the bio technology industry
- 1,601 domestic biologics-establishment inspections were estimated for FDA fiscal year 2024 in the United States.[60]
- 689 blood-bank inspections were estimated for FDA fiscal year 2024 in the United States.[60]
- 43% of U.S. small and medium-sized biotech regulatory, safety and quality respondents cited compliance performance as a main success measure in 2024.[92]
- 90% of parties receiving FDA ClinicalTrials.gov noncompliance notices had subsequently posted required information in 2025 in the United States.[60]
- 14 warning letters concerning clinical-trial compliance were issued by FDA in 2025 in the United States.[60]
Risk Management in the pharmaceuticals and biotech sector (sector benchmark)
- 44% of global life science firms reported no standardized or consistently effective intellectual-property risk-management process in 2024.[93]
- 90% of clinical trials managed by surveyed CROs included at least one risk-based monitoring or risk-based quality-management component in 2025.[94]
- 81% of middle-market life sciences companies said risk management was a top priority, rising to 90% among the fastest-growing organizations.[95]
- 52% of middle-market life sciences companies reported having a business continuity plan in place.[95]
- 85% of global life science firms had a formal business continuity process covering the whole business in 2024.[93]
Cybersecurity in the pharmaceuticals and biotech sector (sector benchmark)
- 40% of surveyed pharmaceutical businesses experienced outages affecting productivity, safety, compliance, revenue, or brand image.[96]
- 98% of surveyed pharmaceutical firms experienced at least one cybersecurity intrusion in the 12 months covered by Fortinet’s 2021 survey.[96]
- 52% of surveyed middle-market life sciences companies reported experiencing a cybersecurity breach.[95]
- 27% of healthcare, biotechnology, and pharmaceutical respondents had little or no confidence in identifying where their data was stored in 2025.[97]
- 28% of surveyed pharmaceutical businesses lost business-critical data or intellectual property because of cybersecurity incidents.[96]
Data Privacy in the pharmaceuticals and biotech sector (sector benchmark)
- 66% of pharma, biotech, and medical-device respondents said patient privacy presented a challenge when complying with journal data-sharing policies in 2024.[98]
- 39% of surveyed pharmaceuticals and life sciences organizations said they tagged and classified around three-quarters of their unstructured data in 2024.[99]
- 84% of surveyed pharmaceuticals and life sciences organizations said measuring and managing sensitive-content compliance required some to significant improvement in 2024.[99]
- Stricter privacy regulation was associated with an approximately 39% reduction in R&D spending by global pharmaceutical and biotechnology firms four years after implementation.[100]
- 61% of surveyed pharmaceuticals and life sciences organizations identified GDPR as a top-two privacy and compliance focus in 2024.[99]
Crisis Management in the pharmaceuticals and biotech sector (sector benchmark)
- 48% of surveyed global life science firms identified natural disasters as a major supply-chain risk for the following two years.[93]
- 40% of surveyed pharmaceutical firms maintained inventory buffers of one to three months to protect against supply-chain disruption.[101]
- 61% of surveyed global life science firms identified panic buying and stockpiling as a major supply-chain risk for the following two years.[93]
- 52% of surveyed global life science firms identified contract-manufacturing issues as a major supply-chain risk for the following two years.[93]
- 50% of surveyed global life science firms identified logistics and warehousing shortages as a major supply-chain risk for the following two years.[93]
Governance in the bio technology industry
- 46.9% of biotechnology board members chaired at least one committee in fiscal year 2023 in the United States.[102]
- 14% of biotechnology CEOs had a company share-ownership requirement in fiscal year 2023 in the United States.[102]
- 96% of biotechnology companies had a set annual cash board retainer in fiscal year 2023 in the United States.[102]
- 97% of biotechnology directors received an equity grant in fiscal year 2023 in the United States.[102]
- 1,360 biotechnology-company board members were covered by a U.S. governance and compensation study for fiscal year 2023.[102]
15 Statistics
Globalization & Expansion
Cross-border capacity and patient-facing models show measurable uptake, including 11% of global biotechnology greenfield foreign direct investment going to China during 2014–2024.
Globalization in the bio technology industry
- 11% of global biotechnology greenfield foreign direct investment went to China during 2014–2024.[103]
- 31% of global biotechnology greenfield foreign direct investment went to the United States between 2003 and 2024.[103]
- Canadian biotechnology foreign direct investment increased from $7 million in 2019 to $390 million in 2021.[103]
- Singaporean biotechnology foreign direct investment increased from $7 million in 2019 to $330 million in 2021.[103]
- 13% of global biotechnology greenfield foreign direct investment went to China between 2003 and 2024.[103]
Cultural adaptation in the bio technology industry
- 35% of biopharma survey respondents reported using remote monitoring to support patient participation in 2024.[9]
- 39% of biopharma survey respondents reported using data or technology to identify target patients in 2024.[9]
- 16% of US patient groups reported receiving advocacy training from pharmaceutical companies in 2024.[104]
- 37% of biopharma survey respondents reported using patient-centric platforms or applications in 2024.[9]
- 35% of biopharma survey respondents reported using patient education as a recruitment strategy in 2024.[9]
Supplier management in the bio technology industry
- 73% of life-sciences companies reported partnerships with other life-sciences organizations in 2025.[23]
- Nearly 90% of US biotechnology companies relied on imported components for at least half of their FDA-approved products in 2025.[22]
- 28% of outsourced commercial manufacturing was handled through preferred-provider relationships in the reported biopharmaceutical outsourcing survey.[105]
- 68% of life-sciences organizations reported partnerships with other life-sciences organizations in 2025.[23]
- 45% of manufacturing outsourcers reported using consultants to guide contract-development-and-manufacturing-organization selection.[106]
Stakeholder management in the bio technology industry
- 54% of rare-disease biopharma survey respondents said patient-advocacy relationships improved their understanding of patient needs.[9]
- 33% of rare-disease biopharma survey respondents said patient-advocacy relationships provided first-hand patient feedback.[9]
- 25% of responding US patient groups reported active involvement in pharmaceutical R&D processes in 2024.[104]
- 37% of rare-disease biopharma respondents said their company used both internal and external resources to maintain patient-advocacy relationships.[9]
- 83% of responding US patient groups reported receiving funding from pharmaceutical companies in 2024.[104]
Distribution channels in the bio technology industry
- 49,500 jobs were added by US medical, dental and hospital equipment wholesalers between 2021 and 2025.[22]
- IQVIA's US National Sales Perspectives dataset represents 90% of the pharmaceutical market across retail, mail and non-retail channels.[64]
- Nearly 69,000 US establishments operated in bioscience-related distribution in 2025.[22]
- More than 650 million US-branded prescriptions were filled in 2024.[64]
- More than 7 billion prescriptions were filled in the United States in 2024.[64]
Key questions about the bio technology industry
What is the global biotechnology market size in 2025?
What growth rate should we use for 2026–2034?
Which companies lead the bio technology industry?
Which technology shifts show up most in 2026 adoption data?
How fragmented is the biotechnology market by company base in the United States?
How does regulation differ by region for biological products?
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
Samuel Norberg. (2026, November 10). Bio Technology Industry Statistics. Gitnux. https://gitnux.org/bio-technology-industry-statistics
Samuel Norberg. "Bio Technology Industry Statistics." Gitnux, 10 Nov 2026, https://gitnux.org/bio-technology-industry-statistics.
Samuel Norberg. 2026. "Bio Technology Industry Statistics." Gitnux. https://gitnux.org/bio-technology-industry-statistics.
Sources & references
120 sources cited across this report
prnewswire.com
mckinsey.de
gartner.com
test.benchling.com
assets.kpmg.com
- techresearchinfo.com
eu-assets.contentstack.com
spectaris.de
ppd.com
pmlive.com
ispe.org
insights.indegene.com
deloitte.com
pharmamanufacturing.com
salesforce.com
veeva.com
capgemini.com
pistoiaalliance.org
zs.com
bio.org
ey.com
williamblair.com
biotechgate.com
stifel.com
- bioutah.org
- lifesciencesworkforce.org
- 4413123.fs1.hubspotusercontent-na1.net
- biotechbenefits.com
connect.gigroup.com
- innovatebio.org
- jthelander.com
naceweb.org
massbio.org
- biobuzz.io
cultureamp.com
- amneal.com
- scienceandmedicinegroup.com
link.springer.com
qualio.com
s202.q4cdn.com
sec.gov
indiaipo.jpmorgan.com
- succession.bio
scileads.com
lifescienceleader.com
fiercepharma.com
- scorrmarketing.com
azonetwork.com
- brand-news.it
sermo.com
jamanetwork.com
- nibrt.ie
pharmtech.com
web-assets.bcg.com
mckinsey.com
- bioprocessonline.com
fda.gov
- visium.com
assets.cfr.org
- nitesh_cp.rodpub.com
iqvia.com
glginsights.com
richmondfed.org
academic.oup.com
bioprocessintl.com
fiercebiotech.com
siblisresearch.com
pacificresearch.org
- bioalberta.com
astrazeneca.com
pmc.ncbi.nlm.nih.gov
reddit.com
statnews.com
- makingpharmaindustry.it
sciencedirect.com
- 21176235.fs1.hubspotusercontent-na1.net
aphl.org
labmanager.com
nature.com
- static.seitosei-presse.com
ethifinance.com
assets.fenwick.com
onlinelibrary.wiley.com
tandfonline.com
frontiersin.org
- bpsalliance.org
mygreenlab.org
- thejournalofmhealth.com
- lifesciencesny.org
acrohealth.org
middlemarketcenter.org
fortinet.com
cpl.thalesgroup.com
- openpharma.blog
kiteworks.com
etla.fi
- insights.economistenterprise.com
home.bedfordgroup.com
oecd.org
- patient-view.com
outsourcedpharma.com
- isrreports.com
fortunebusinessinsights.com
health.ec.europa.eu
grandviewresearch.com
lilly.com
roche.com
annualreport.novonordisk.com
investors.vrtx.com
abbvie.com
amgen.com
investor.incyte.com
investor.regeneron.com
biomarin.com
ir.ionis.com
Social media in the bio technology industry